Skip to content

Advertisement

  • Research
  • Open Access

Microglia P2X4 receptor contributes to central sensitization following recurrent nitroglycerin stimulation

Journal of Neuroinflammation201815:245

https://doi.org/10.1186/s12974-018-1285-3

  • Received: 6 May 2018
  • Accepted: 20 August 2018
  • Published:

Abstract

Background

The mechanism underlying migraine chronification remains unclear. Central sensitization may account for this progression. The microglia P2X4 receptor (P2X4R) plays a pivotal role in the central sensitization of inflammatory and neuropathic pain, but there is no information about P2X4R in migraine. Therefore, the aim of this study was to identify the precise role of microglia P2X4R in chronic migraine (CM).

Methods

We used an animal model with recurrent intermittent administration of nitroglycerin (NTG), which closely mimics CM. NTG-induced basal and acute mechanical hypersensitivity were evaluated using the von Frey filament test. Then, we detected Iba1 immunoreactivity (Iba1-IR) and P2X4R expression in the trigeminal nucleus caudalis (TNC). To understand the effect of microglia and P2X4R on central sensitization of CM, we examined whether minocycline, an inhibitor of microglia activation, and 5-BDBD, a P2X4R antagonist, altered NTG-induced mechanical hyperalgesia. In addition, we also evaluated the effect of 5-BDBD on c-Fos and calcitonin gene-related peptide (CGRP) expression within the TNC.

Results

Chronic intermittent administration of NTG resulted in acute and chronic basal mechanical hyperalgesia, accompanied with microglia activation and upregulation of P2X4R expression. Minocycline significantly decreased basal pain hypersensitivity but did not alter acute NTG-induced hyperalgesia. Minocycline also reduced microglia activation. 5-BDBD completely blocked the basal and acute hyperalgesia induced by NTG. This effect was associated with a significant inhibition of the NTG-induced increase in c-Fos protein and CGRP release in the TNC.

Conclusions

Our results indicate that blocking microglia activation may have an effect on the prevention of migraine chronification. Moreover, we speculate that the P2X4R may be implicated in the microglia-neuronal signal in the TNC, which contributes to the central sensitization of CM.

Keywords

  • P2X4R
  • Microglia
  • Migraine
  • Nitroglycerin
  • Animal model

Background

Migraine is a complex, severe neurological disease that has been intensively researched. Each year, 2.5% of episodic migraine patients convert into chronic migraine (CM) [1]. With chronification, there are structural, physiologic, and biochemical alterations in the brain that lead to an increase in the frequency of headache and a poor response to therapy [2]. The mechanism of migraine chronification is still unclear. One of the leading theories is the central sensitization hypothesis, which proposes that there is an increase in the excitability of central neurons in the trigeminal nociceptive pathway, principally the trigeminal nucleus caudalis (TNC) [3].

Neurons, as the center of pain information processing, transmission, and integration, have been the focus of central sensitization. Therefore, many “classic” analgesic drugs primarily target neurons. But increasing evidence suggests that activation of microglia directly or indirectly influences the establishment of neuronal hyperexcitability, which plays an important role in the development or maintenance of chronic pain states, including migraine [46]. Tsubasa Takizawa and colleagues noted that multiple cortical spreading depression (CSD), considered to be associated with migraine aura, could lead to microglia activation [5]. Meanwhile, a study indicated that repeated inflammatory soup (IS) infusions stimulated the dura mater, which also can lead to microglia activation [7]. Therefore, a better understanding of the molecular cross-talk mechanism between TNC neurons and surrounding microglia could help lead to a profound understanding of migraine chronification.

Adenosine triphosphate (ATP), as an algogenic substance, mediates either the activation or the sensitization of nociceptive neurons via ATP receptors (ionotropic P2X-purinoceptor or metabotropic P2Y-purinoceptor). The potential involvement of the purinergic signaling in the pathophysiology of migraine was put forward more than 30 years ago [8]. Since then, the roles of different types of purinergic receptors have been examined in cellular and animal models of migraine, among which, the role of P2X3R is the most widely studied [911]. Moreover, these studies mainly focused on the peripheral sensitization mechanism of migraine or CSD, whereas few focused on central sensitization mechanism.

Activated microglia induce or enhance expression of various purinergic P2 receptor. P2X4R belongs to the P2X family of receptors, which are mainly expressed in microglia. Extensive lines of evidence indicate that P2X4R-positive microglia play a pivotal role in the mechanism of neuropathic pain. Inhibiting the expression and function of P2X4R suppresses the central sensitization of neuropathic pain [12]. However, the role of P2X4R has not been examined in any animal model of migraine.

Therefore, the objective of this study was to investigate the role of microglia and P2X4R in CM. A mouse model of CM was developed using chronic intermittent nitroglycerin (NTG) injection, and then, the effect of the pharmacological blockade of microglia activation and P2X4R on NTG-induced mechanical hyperalgesia, c-Fos, and calcitonin gene-related peptide (CGRP) expression in the TNC was examined.

Methods

Animals

Male C57BL/6 mice (weighting 18–20 g, aged 8–10 weeks) were provided by the Experimental Animal Center of Chongqing Medical University (Chongqing, China). All procedures followed the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals. Mice were maintained on a 12-h light/dark cycle under standard laboratory conditions with enough food and water. Experiments were carried out between 9:00 and 15:00. All animals were acclimatized for 1 week before experimental procedures and randomly assigned to experimental groups. Randomized allocation was designed with Excel Software. The procedure was as follows: (1) C67BL/6 mice weighting 18–20 g were selected then numbered. (2) The randomization numbers were created using the “rand()” function of Excel software and sorted by incremental method. (3) Then, according to the order, each 6–8 numbers are divided into different groups.

Drugs and treatments

NTG (Beijing Regent, China) was prepared from a stock solution of 5.0 mg/ml dissolved in 30% alcohol, 30% propylene glycol, and water. NTG was diluted at 1 mg/ml prior to the start of the experiment. The vehicle control was 0.9% saline because there was no significant difference in mechanical thresholds between 0.9% saline and the solution in which NTG was dissolved (6% propylene glycol, 6% alcohol, 0.9% saline). Animals received intraperitoneal (i.p.) injections of 10 mg/kg NTG or vehicle every other day for 9 days (i.e., days 1, 3, 5, 7, and 9) [13].

To understand the effect of microglia and P2X4R on NTG-induced hyperalgesia, we treated the animals with the microglia inhibitor minocycline (MedChemExpress/MCE, American) or the P2X4R-selective antagonist 5-BDBD (Sigma-Aldrich, American). Minocycline and 5-BDBD were dissolved in DMSO solution, which was used as the vehicle control. Minocycline/vehicle or 5-BDBD/vehicle was administered immediately prior to the administration of NTG/saline [14, 15]. The treatment of the mice on testing days was as follows: mice were habituated to the test room, followed by a baseline measurement of mechanical thresholds 15–20 min later and an administration of minocycline (30 mg/kg, i.p.), 5-BDBD (28 mg/kg, i.p.), or vehicle; then, an injection of NTG/saline was given, and 2 h later, acute mechanical responses were tested. This procedure was repeated every other day for 9 days.

Sensory sensitivity testing

All animal behavior testing occurred in light conditions, between 09:00 and 15:00. For the determination of mechanical sensitivity, the threshold for responses to punctuate mechanical stimuli (mechanical hyperalgesia) was tested according to the up-and-down method. The plantar surface of the animal hind paw was stimulated with a series of eight von Frey filaments (bending force ranging from 0.01 to 2 g) from the underside of the mesh stand. The 0.4-g von Frey filament was tested first. A response was defined as a withdrawal, shaking, or licking of the paw. In the absence of a response, a heavier filament (up) was used, and in the presence of a response, a lighter filament (down) was tested. Each filament was applied to the skin for 3 s at 1-min intervals. This pattern was followed for a maximum of four filaments following the first response. The evaluating experimenters were blind to the experimental groups.

Quantitative real-time polymerase chain reaction (qRT-PCR)

Mice were euthanized, and the TNC was dissected at 12 h after last NTG injection for qRT-PCR experiments. The tissues were immediately stored in liquid nitrogen. Total RNA was extracted as previously described [16] using an RNAiso Plus reagent (TaKaRa, Dalian), and RNA was quantified spectrophotometrically with NanoDrop (Thermo, USA). Then, cDNA was synthesized using the PrimeScript™ RT Reagent Kit (Takara). P2X4R (p2rx4) mRNA expression are analyzed. Specific primers were obtained from Sangon Biotech (Shanghai, China). The sequences of primers are described as follows: P2X4: 5′-TCG TGT GGG AAA AGG GCT AC-3′ (forward), 5′-GTC TGG TTC ACG GTG ACG AT-3′ (reverse); GAPDH: 5′-ATG ACT CTA CCC ACG GCA AGC T-3′ (forward), 5′-GGA TGC AGG GAT GAT GTT CT-3′ (reverse). GAPDH mRNA was used as an endogenous control for normalization. Quantitative real-time PCR was performed with SYBR® Premix Ex Taq™ II (Takara) with a CFX96 Touch thermocycler (Bio-Rad, USA) according to the instructions. All fluorescence data were processed by a post-PCR data analysis software program. The ΔΔCq method was used to investigate the differences in the gene expression levels.

Western blot analysis

For P2X4R protein detection, TNC was collected 12 h after different NTG injection times. Until measurements, the samples were stored at − 80 °C. Tissues were sonicated in an ice-cold RIPA lysis buffer (Beyotime, China) containing with phenylmethylsulphonyl fluoride (PMSF, Beyotime, China) at 4 °C for 1 h. Protein concentration was measured according to the BCA protein assay method with a BCA Protein Assay Kit (Beyotime, China). Equal amounts of protein (40 μg) were loaded on an SDS-PAGE gel (Beyotime, China), electrophoresed, and transferred to PDVF membranes. Following the transfer, membranes were blocked for 2 h at room temperature in TBST containing 5% non-fat milk and incubated in a primary antibody, rabbit anti-mouse P2X4R polyclonal antibody (1:1000, Abcam). The complete information of all antibodies were included in the Additional file 1. The next day, membranes were incubated in a horseradish peroxidase-conjugated anti-rabbit secondary antibody (1:9000, ZSGB-BIO, China) at 37 °C for 1 h. Immunoblots were then probed with a BeyoECL Plus kit (Beyotime, China) and visualized with an imaging system (Fusion, Germany). β-Actin (1:9000, Proteintech, China) was used as a loading control to normalize protein levels.

Immunohistochemistry and quantification

For c-Fos detection, mice were treated as described above with 5-BDBD or vehicle, and tissue was collected 2 h after the last NTG injection. Mice were anesthetized with 10% chloral hydrate (0.1 ml/10 g) and perfused intracardially with 30 ml of ice-cold 0.9% saline and subsequently perfused with 50 ml ice-cold 4% paraformaldehyde (PFA)/0.1 M PBS (pH 7.4). The whole brain was collected and post-fixed in 4% PFA at 4 °C for 18 h. The medullary segment containing the TNC between + 1 and − 3 mm from the obex was removed. Tissues were immersed in 20% and 30% sucrose in turn. Samples were then frozen, and transverse sections were cut at 10 μm thickness (Leica). For c-Fos staining, sections were incubated in 0.3% H2O2 for 30 min and blocked with 10% normal goat serum in PBST (10% NRST) for 1 h, followed by incubation with anti-c-Fos antibody at 4 °C (1:500, 48 h, Abcam, USA). Sections were incubated for 1 h with a goat anti-rabbit secondary antibody and incubated with an avidin-biotin-complex using a kit (ZSGB-BIO, China). C-Fos primary antibody staining was visualized with DAB.

The TNC region was determined based on morphological appearance under light microscopy using the Mouse Brain Atlas as a reference [17]. Images were observed in a ZEISS Axio Imager A2 microscope under × 10 and × 20 objective lens. Expression of c-Fos was quantified by averaging 6–10 sections containing both sides of the TNC (throughout rostrocaudal extent) per mouse, (n = 7 mice/group). Image analysis was performed by Imagepro-Plus 6.0 software. The c-Fos-positive cells were scored as those with obvious specific nuclear staining. The laminae I–V of TNC were determined manually as area of interest using a rectangular tool. There was no significant difference in the area of TNC across experimental groups (see Additional file 2). All evaluations were performed by an observer blind to the experimental groups.

Immunofluorescence staining and counting

For Iba-1 and P2X4R detection, tissues were collected at 12 h after the last NTG/saline injection. But considering the short half-life of CGRP, tissues were taken at 2 h after last NTG/saline injection for CGRP immunofluorescence staining. The sections were blocked by incubation in 10% normal donkey serum or goat serum at room temperature for 30 min. Sections were incubated with goat anti-mouse Iba-1 polyclonal antibody (1:400, Abcam), rabbit anti-mouse P2X4R antibody (1:80, Abcam), or mouse anti-mouse CGRP antibody (1:100, Santa Cruze) overnight in 4 °C, respectively. The next day, sections were incubated with species-specific fluorophore-labeled secondary antibodies (1:400, Abbkine) for 2 h at room temperature. Nuclei were counter stained with 4′,6-diamidino-2-phenylinodole (DAPI) at 37 °C for 5 min. Sections were viewed under a confocal laser scanning fluorescence microscope (ZEISS, Germany).

The TNC area on the section images was determined as previously described. Subsequently, we calculated the ratio of cross-sectional area immunoreactive for Iba1 in the TNC area and estimated the number of Iba1-IR cells per 1 mm2 of the TNC at × 10 or × 20 magnification using an image analysis software (Image-Pro Plus 6.2, Media Cybernetics). Optical density (OD) values were taken to indicate the quantities of CGRP and calculated by correcting the intensity of stained areas for the intensity of the background. The two sides of the TNC from six sections per animal (n = 6 mice/group) were included in the analysis.

Statistical analysis

Data are expressed as mean ± SD. All statistical analyses were performed by GraphPad Prism version 6.0 (Graph Pad Software Inc., San Diego, CA). All data were tested for normality using the Kolmogorov-Smirnov (K-S) normality tests and considered normally distributed data. F test or Bartlett’s test were used to compare variances. Behavioral results were analyzed using a two-way RM ANOVA, with drug and time as factors. In this case, all groups were compared to responses on day 1, and to the VEH-VEH group. For Iba-1 immunofluorescence and P2X4R qRT-PCR experiments, data were analyzed using unpaired t tests. If the variances were significantly different, unpaired t test with Welch’s correction was used. The expression of P2X4R and CGRP and the number of c-Fos-positive nuclei were analyzed using one-way ANOVA followed by Tukey’s multiple comparison test, and the variance difference was not significant. A significance level of p < 0.05 was used.

Results

Effect of recurrent NTG stimulation on microglia response in the TNC

To study the role of NTG on microglia response, we performed a qualitative immunohistochemical assessment of Iba1 (microglial specific marker) in the TNC. As shown in Fig. 1, Iba1-IR was observed sparsely in the TNC in the vehicle group (VEH). However, after recurrent administration of NTG for 9 days (NTG 9d), the number of Iba1-labeled cells (179.4 ± 24.3/mm2) was significantly higher than that in the vehicle group (472.6 ± 48.8/mm2, p < 0.05) (Fig. 1b). In addition, marked hypertrophy of Iba1-IR cells was observed in the NTG 9d group. Morphologically, the majority of the hypertrophic microglia appeared to be ramified microglia, and only a few ameboid microglia were identified (Fig. 1d). Quantitatively, the ratio of the cross-sectional area of Iba1-IR cells to the TNC area was 0.56 ± 0.1% in the vehicle group and 1.50 ± 0.2% in the NTG 9d group (Fig. 1c). There was a significant increase in the NTG 9d group compared to that in the vehicle group (p < 0.05).
Fig. 1
Fig. 1

Effect of recurrent NTG stimulation on microglia response in the TNC. a The white dotted line frame indicates the TNC regions. b Quantitative analysis of the number of Iba1-IR-positive cells. c The ratio of area immunoreactive for Iba1 to the total area of the ipsilateral TNC in the vehicle group (VEH) and the NTG 9d group (NTG intermittent injection for 9 days). Unpaired t test, n = 6/group. ***p < 0.001. d Immunostaining of the TNC for Iba1 in VEH (the upper row) and the NTG 9d group (the lower row); nuclear staining was performed with DAPI (the middle column). Scar bar, 100 μm

We speculated that microglial activation correlated with the NTG-induced pain hypersensitivity. Therefore, we intraperitoneally injected an inhibitor of microglial activation, minocycline (30 mg/kg). In agreement with previous findings, repetitive intermittent NTG injection (NTG-VEH) produced a significant time-dependent chronic basal mechanical hyperalgesia as assessed by testing prior to each administration of NTG (Fig. 2a). In addition, every NTG administration evoked significant acute mechanical hyperalgesia on each test day as assessed by testing 2 h after NTG injection (Fig. 2b). Minocycline (NTG-Mino) significantly decreased the basal pain hypersensitivity but did not alter post-treatment hyperalgesia induce by NTG. Only minocycline administration (VEH-Mino) did not provoke any significant change in the mechanical threshold.
Fig. 2
Fig. 2

Effect of minocycline on NTG-induced mechanical hypersensitivity and microglia response. Prior to NTG/saline administration, mice were treated with vehicle or minocycline (Mino, 30 mg/kg, i.p.) every other day for 9 days. a Chronic treatment with minocycline significantly altered basal hypersensitivity. p < 0.01 for drug, time, and interaction. Two-way RM ANOVA and Bonferroni post hoc analysis. n = 8/group. ***p < 0.001 compared to the VEH-VEH group. b Post-treatment responses were assessed 2 h following NTG administration. Minocycline did not prevent acute NTG-induced hyperalgesia. p < 0.001 effect of drug, but no significant effect of time or interaction, two-way RM ANOVA. n = 8/group. c Immunostaining of the TNC for Iba1 in the NTG group and the NTG + Mino group on day 9; scale bar, 50 μm. d Quantitative analysis of the number of Iba1-positive cells. e The ratio of area immunoreactive for Iba1 to the total area of the ipsilateral TNC. Unpaired t test, n = 6/group. ***p < 0.001

Compared with the NTG group (NTG), minocycline (NTG + Mino) reduced the number of Iba1-labeled cells on the ninth day (532.9 ± 34.6/mm2 vs 146.5 ± 16.7/mm2, p < 0.05). Meanwhile, minocycline also reduced the ratio of the cross-sectional area of Iba1-IR cells to the TNC area (1.49 ± 0.2% vs 0.44 ± 0.1%, p < 0.05) (Fig. 2ce). These results indicated that migraine-associated pain evoked by NTG may depend on microglia activation.

Recurrent NTG injection increased the expression levels of the P2X4R

We examined the level of P2X4R expression in the TNC and found that P2X4R mRNA and protein levels increased markedly after recurrent NTG stimulation (Fig. 3ac); the increase in P2X4R protein was detected as early as day 3. On the last day of NTG injection, the expression of P2X4R was still higher, which is in line with recurrent NTG-induced basal hyperalgesia. To identify the cell type of expressing P2X4R, we performed double immunofluorescence labeling for P2X4R and Iba1 (Fig. 3d, e). We found that almost all P2X4R-positive cells were double-labeled with Iba1, indicating that P2X4R was expressed in microglia, as shown in previous research [18].
Fig. 3
Fig. 3

Expression profile of P2X4R after chronic intermittent administration of NTG. a, b Western blot assay for the protein expression of P2X4R on different days. One-way ANOVA and Tukey’s multiple comparison test. n = 5/group, **p < 0.01, ***p < 0.001, versus the vehicle group (VEH). c qRT-PCR analysis for the mRNA expression of P2X4R between the vehicle group and the NTG 9d group (NTG intermittent injection for 9 days). Unpaired t test, n = 6/group. ***p < 0.001. d, e Double immunofluorescence labeling of P2X4R (green) and Iba1 (red) in VEH and NTG 9d groups. Most P2X4R-positive cells are double-labeled (yellow) with Iba1. Scale bars, 20 μm

P2X4R antagonist 5-BDBD prevented NTG-induced mechanical hypersensitivity

Because we found that P2X4R expression was markedly upregulated in the TNC after NTG injection, we predicted that suppressing the function of P2X4R could prevent NTG-induced hypersensitivity. Mice were treated with the P2X4R antagonist 5-BDBD (28 mg/kg) or vehicle prior to injection of NTG or saline. We observed that chronic treatment with 5-BDBD (NTG + 5BDBD) completely blocked the basal hypersensitivity (Fig. 4a) and the acute NTG-induced hyperalgesia (Fig. 4b). Only 5-BDBD administration (VEH-5BDBD) did not provoke any significant change in mechanical threshold. These results indicated that P2X4R may be the key receptor participating in NTG-induced hyperalgesia.
Fig. 4
Fig. 4

Chronic treatment with 5-BDBD (P2X4R antagonists) inhibited NTG-induced basal and acute hyperalgesia. Prior to NTG/saline administration, mice were treated with vehicle or 5-BDBD (28 mg/kg, i.p.) every other day for 9 days. a Basal hyperalgesia induced by recurrent NTG injection was completely blocked by 5-BDBD. p < 0.01 for drug, time, and interaction; two-way RM ANOVA and Bonferroni post hoc analysis; n = 8/group. ***p < 0.001 compared to the VEH-VEH group. b Every NTG injection evoked acute hyperalgesia, which was also blocked by 5-BDBD. p < 0.01 for drug, no significant effect of time or interaction. Two-way RM ANOVA, n = 8/group

5-BDBD reduced NTG-induced c-Fos expression in the TNC

c-Fos has been extensively used as a reliable marker for the activation of nociceptive neurons after noxious stimulation. In line with previous studies [19], NTG evoked c-Fos expression in the superficial layer of the TNC, which may underly the NTG-induced mechanical hypersensitivity (Fig. 5a). Compared with the vehicle group (VEH), the number of c-Fos-IR cells was significantly increased after recurrent NTG stimulation (NTG) (26.1 ± 7.5 vs 84.9 ± 11.8 cells/section, p < 0.001). Treatment with 5-BDBD (NTG + 5BDBD) elicited a reduction in c-Fos compared with the NTG group (34.1 ± 8.7 vs 84.9 ± 11.8 cells/section, p < 0.001) (Fig. 5b). These results supported the notion that P2X4R might activate the central region of trigeminovascular system to potentiate central sensitization.
Fig. 5
Fig. 5

Change in c-Fos immunoreactivity in the TNC. a Representative images of c-Fos immunoreactivity in the VEH, NTG, and NTG + 5BDBD groups under × 10 objective lens (the upper row) and × 20 objective lens (the lower row). b Quantification of average number of c-Fos particles revealed that NTG significantly increased c-Fos expression in the TNC. Pretreatment with 5-BDBD inhibited NTG-induced c-Fos expression. One-way ANOVA and Tukey’s multiple comparison test. ***p < 0.001 compared to VEH, ###p < 0.001 compared to NTG group. n = 7/group

Effect of 5-BDBD on CGRP protein expression in the TNC

CGRP, an important mediator of migraine pathogenesis, plays a pivotal role in central sensitization in the TNC. NTG induces a hyperalgesia condition associated with CGRP released from central terminals of TG neurons in the brainstem. After repeated NTG injection, the OD of CGRP-immunoreactive fibers was decreased in the superficial layers of TNC than that in the vehicle group (p < 0.001, Fig. 6a, b). The immunopositivity decrease was attenuated by pretreatment with 5-BDBD (p < 0.01). These results indicated that P2X4R may be involved in cross-talk mechanism between TNC neurons and microglia.
Fig. 6
Fig. 6

Change in CGRP immunoreactivity in the TNC. a Representative photos of CGRP-immunoreactive staining in the TNC of the VEH, NTG, and NTG + 5-BDBD groups under × 10 objective lens (the upper row) or and × 20 objective lens (the lower row). The white rectangle frame indicates the representative anatomical site observed under × 20objective lens. b Compared to the VEH group, the OD of area covered by CGRP-immunoreactive fibers was decreased in the NTG group. Pretreatment with 5-BDBD attenuated the decrease of CGRP immunopositivity. The OD of staining fibers was not significantly different at the vehicle group and NTG + 5-BDBD group. One-way ANOVA and Tukey’s multiple comparison test. n = 6/group. **p < 0.01 compared to the VEH, ##p < 0.01 compared to the NTG group

Discussion

The aim of this study was to investigate whether microglia P2X4R in the TNC contributes to central sensitization in CM. Following chronic intermittent NTG administration for 9 days, an acute hyperalgesia and prolonged basal hypersensitivity were induced in mice, as manifested by a decrease in the mechanical threshold in response to von Frey filaments. In these recurrent NTG injection mice, we found enhancement of Iba1-immunoreactivity and P2X4R expression in the TNC. Pretreatment with minocycline alleviated chronic basal hyperalgesia and microglia activation, but not acute NTG-induced hyperalgesia. The P2X4R inhibitor, 5-BDBD, completely prevented the acute and chronic mechanical hyperalgesia. Recurrent NTG-induced c-Fos expression and CGRP release in the TNC were also attenuated after 5-BDBD treatment. All of these results suggest that aberrant microglia activation and P2X4R expression may be the critical component regulating migraine chronification.

Animal model of chronic migraine

We used chronic intermittent NTG injection (10 mg/kg, i.p.) to build a CM animal model, described recently by Pradhan et al. [13]. NTG is a widely used migraine trigger in human clinical experiments [20]. Acute NTG-induced thermal and mechanical hyperalgesia in rodents has been used as an animal model for migraine. Moreover, chronic administration of NTG to mice resulted in not only acute mechanical hyperalgesia after each exposure but also sustained and progressive decrease in the basal mechanical threshold of hind paws. These results are consistent with the clinical observations of CM patients in whom hyperalgesia or allodynia may occur in both cephalic region and extracephalic region, such as the neck and forearms. The appearance of cutaneous allodynia following NTG likely reflects the development of central sensitization, which may be mediated through abnormal neuronal excitability within the trigeminal nucleus caudalis (TNC) and thalamus. Some researches determined the mechanical sensitivity of periorbital region and hind paws. Similar to the hind paws, NTG treatment also induces the periorbital hyperalgesia [21]. So in our study, we only tested the mechanical sensitivity of animal hind paws. This chronic basal hyperalgesia persists for days following cessation of NTG administration. Further, repeated administration of NTG has also been shown to produce photophobia, hypoactivity, and facial grimace behaviors [22]. Therefore, this is a reliable animal model for studying chronic migraine-associated pain.

In our study, recurrent NTG administration produced a significant basal sensitization, which was first observed after two NTG injections (i.e., day 5). In addition, on each test day, NTG also evoked significant acute mechanical hyperalgesia.

Chronic migraine and microglia

Most research on central sensitization mainly focuses on neuronal function, ignoring the potential contribution of gliocytes. Extensive studies about animal models of neuropathic pain have indicated that spinal glial activation, especially microglia, and the subsequent secretion of mediators have an important role in initiating or maintaining an aberrant hyperalgesia state [23].

Recently, some evidences have indicated that altered microglia function may be involved in the pathophysiological mechanisms of migraine. It is known that recurrent CSD is the upstream neural signal change in CM [24]. A recent study indicated that multiple CSD caused a marked enlargement of microglia [5] and release of microglia cytokine, such as IL-1β and TNF-α. These cytokines also affected the threshold and amplitude of CSD [2527]. In addition, Cui Y and colleagues also found in a PET study that microglia were activated in the rat brain as a consequence of CSD stimulation [28].

In addition, Nathan Fried used another CM animal model that was built with repeated IS stimulation of dura mater. Then, the author indicated that no microglia activation was observed during the episodic stage (only two IS stimulations), but microglia activation was increased in the TNC during the chronic stage (total of ten IS stimulations). Importantly, minocycline treatment could inhibit trigeminal sensitivity after recurrent IS stimulation [7].

Our results showed that after recurrent NTG injection, the number of Iba1-IR cells was increased in the TNC. Minocycline significantly attenuated the NTG-induced basal mechanical hyperalgesia and immunoreactive staining for Iba1, but it did not alter acute hyperalgesia. Thus, inhibition of microglial activation can be used as a potential preventive therapy rather than an acute analgesic. However, in addition to its effects on microglia, minocycline has been shown to have broad effects on immune cells, such as astrocytes, oligodendrocytes, and macrophages. As such, data generated with minocycline need to be interpreted with caution. We cannot rule out that minocycline may affect other immune cells to decrease NTG-induced hypersensitivity. In addition, the cellular mechanism that underlies the crosstalk between microglia and neurons of the TNC needs further study.

Chronic migraine and purinergic signal

Although N-methyl-D-aspartate (NMDA) and non-NMDA receptors are thought to be fundamental mechanisms underlying central sensitization, many studies suggest that purinergic receptor may be involved [29]. In the purinergic hypothesis for migraine, ATP has been implicated in migraine via stimulating cerebral vasodilatation and primary afferent nerve terminals located in the cerebral microvasculature.

A substantial number of studies have revealed an increasing microglia-specific P2X4R expression in the spinal cord in diverse animal models of neuropathic pain. In our experiments, a similar change in P2X4R expression in the TNC was found. Furthermore, the P2X4R-specific inhibitor, 5-BDBD, inhibits P2X4R-mediated Ca2+ signals and inward ion currents in vitro and is known to permeate the blood-brain barrier [30]. We found that 5-BDBD, unlike minocycline, effectively prevented both basal hyperalgesia and acute NTG-induced hyperalgesia. P2X4R is also expressed in other areas of the brain; therefore, we cannot exclude the possibility that 5-BDBD acts on other migraine-related regions including the periaqueductal gray (PAG), sensory cortical region, or even satellite glial cells (SGCs) of the trigeminal ganglion (TG) [31]. In addition, minocycline does not affect the activation of SGCs in the TG [32, 33]. Therefore, minocycline and 5-BDBD may play different roles in NTG-associated hyperalgesia.

P2X4R, c-Fos, and CGRP

C-Fos, the protein of the protooncogene c-fos, has been widely used as a marker for neuronal activation. Most treatments inhibiting c-Fos similarly affect pain-related behaviors. In addition, c-Fos has been implicated in central sensitization via transcriptional regulation of prodynorphin [34]. Studies using different animal models of migraine (including injection of NTG, IS, or CSD stimulation) all evoked an increase expression of c-Fos within the TNC, especially in laminae I and II [35]. In our study, a chronic NTG model significantly induced c-Fos expression in the superficial lamina of the TNC, where the first-order trigeminal neurons make synaptic contact with the second-order neurons. In addition, 5-BDBD alleviated NTG-induced c-Fos expression, which may underlie the reduction in the pain threshold.

CGRP, as a key neuropeptide of the trigeminal system, is implicated in the peripheral and central sensitization of migraine. During migraine attacks, the levels of CGRP in patient serum, saliva, and cerebrospinal fluid are elevated. In the animal model of migraine, NTG injection results in an increase of CGRP in the blood, dura mater, TG, and TNC [36]. However, some previous studies found that NTG treatment induced a decrease in the area occupied by CGRP-immunoreactive fibers and in CGRP protein expression by western blot in the TNC [37, 38]. These results indicated that this is a probably consequence of an increase release of CGRP from storage vesicles in the central terminals of trigeminal afferents. The majority of CGRP is synthesized in cell bodies of TG. Then, CGRP protein is transported in vesicles along the nerve fibers to the nerve endings in the TNC or solitary tract nucleus [39]. In our study, 2 h after NTG treatment was the time of sampling for determining the CGRP protein levels; these periods might be insufficient for the depleted CGRP to be resynthesized and to be transported to TNC. So we found a reduction of CGRP staining after repeated NTG injection. In addition, NO synthesis or cGMP activation may be involved in the mechanism of NTG-induced CGRP release [40].

In our studies, CGRP-immunoreactive fibers were mainly distributed in the superficial of TNC, which are associated primarily with processing nociceptive information. 5-BDBD pretreatment mitigated the NTG-induced CGRP immunoreactivity changes in the TNC, modulating the trigeminal system activation. The cellular mechanism underlying the P2X4R-induced CGRP release may be related to brain-derived neurotrophic factor (BDNF). Previous studies demonstrated that BDNF is released from ATP-stimulated microglia via the P2X4R signaling pathway in vitro and vivo [41]. In addition, BDNF, acting via trkB receptors, can regulate the expression and release of CGRP from sensory neurons [42].

Conclusion

Chronic migraine occurs with central sensitization of trigeminal sensory pathways that involve microglial activation and increased expression of P2X4R. Inhibition of microglia may be effective in preventing migraine chronification but be ineffective in aborting an acute migraine attack. In addition, we speculated that P2X4R may be implicated in microglia-neuronal signaling in the TNC. Inhibition of P2X4R function might be a potential therapeutic option for CM.

Abbreviations

ATP: 

Adenosine triphosphate

BDNF: 

Brain-derived neurotrophic factor

CGRP: 

Calcitonin gene-related peptide

CM: 

Chronic migraine

CSD: 

Cortical spreading depression

IS: 

Inflammatory soup

NMDA: 

N-Methyl-d-aspartate

OD: 

Optical density

PAG: 

Periaqueductal gray

qRT-PCR: 

Quantitative real-time polymerase chain reaction

SGC: 

Satellite glial cells

TG: 

Trigeminal ganglion

TNC: 

Trigeminal nucleus caudalis

Declarations

Funding

This study was supported by the National Natural Science Foundation of China [No. 81671092].

Availability of data and materials

The data used in this article are available if necessary.

Authors’ contributions

TL designed the study, collected and analyzed the data, and drafted the manuscript. JZ and LC handled the funding, provided useful advice on the design of this study, and supervised the experimental work and revision of this manuscript. WH, QP, SZ, XZ, QC, and CL performed part of the experiments. All authors read and approved the final manuscript.

Ethics approval

Our manuscript data were collected from animals, and the study was approved by the Ethics Committee for Animal Experimentation of Chongqing Medical University (Document number SYXK (渝) 2012–0001).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, 1st Youyi Road, Yuzhong District, Chongqing, 400016, China
(2)
Laboratory Research Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China

References

  1. Schwedt TJ. Chronic migraine. BMJ. 2014;348:g1416.View ArticlePubMedGoogle Scholar
  2. Aurora SK, Brin MF. Chronic migraine: an update on physiology, imaging, and the mechanism of action of two available pharmacologic therapies. Headache. 2017;57:109–25.View ArticlePubMedGoogle Scholar
  3. Mathew NT. Pathophysiology of chronic migraine and mode of action of preventive medications. Headache. 2011;51(Suppl 2):84–92.View ArticlePubMedGoogle Scholar
  4. Bartley J. Could glial activation be a factor in migraine? Med Hypotheses. 2009;72:255–7.View ArticlePubMedGoogle Scholar
  5. Takizawa T, Shibata M, Kayama Y, Shimizu T, Toriumi H, Ebine T, Unekawa M, Koh A, Yoshimura A, Suzuki N. High-mobility group box 1 is an important mediator of microglial activation induced by cortical spreading depression. J Cereb Blood Flow Metab. 2017;37:890–901.View ArticlePubMedGoogle Scholar
  6. Su M, Ran Y, He Z, Zhang M, Hu G, Tang W, Zhao D, Yu S. Inhibition of toll-like receptor 4 alleviates hyperalgesia induced by acute dural inflammation in experimental migraine. Mol Pain. 2018;14:2070408908.Google Scholar
  7. Fried NT, Maxwell CR, Elliott MB, Oshinsky ML. Region-specific disruption of the blood-brain barrier following repeated inflammatory dural stimulation in a rat model of chronic trigeminal allodynia. Cephalalgia. 2018;38:674–89.View ArticlePubMedGoogle Scholar
  8. Burnstock G. Pathophysiology of migraine: a new hypothesis. Lancet. 1981;1:1397–9.View ArticlePubMedGoogle Scholar
  9. Nowodworska A, van den Maagdenberg A, Nistri A, Fabbretti E. In situ imaging reveals properties of purinergic signalling in trigeminal sensory ganglia in vitro. Purinergic Signal. 2017;13:511–20.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Fabbretti E, D'Arco M, Fabbro A, Simonetti M, Nistri A, Giniatullin R. Delayed upregulation of ATP P2X3 receptors of trigeminal sensory neurons by calcitonin gene-related peptide. J Neurosci. 2006;26:6163–71.View ArticlePubMedGoogle Scholar
  11. Magni G, Merli D, Verderio C, Abbracchio MP, Ceruti S. P2Y2 receptor antagonists as anti-allodynic agents in acute and sub-chronic trigeminal sensitization: role of satellite glial cells. Glia. 2015;63:1256–69.View ArticlePubMedGoogle Scholar
  12. Tsuda M, Masuda T, Tozaki-Saitoh H, Inoue K. P2X4 receptors and neuropathic pain. Front Cell Neurosci. 2013;7:191.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Pradhan AA, Smith ML, McGuire B, Tarash I, Evans CJ, Charles A. Characterization of a novel model of chronic migraine. Pain. 2014;155:269–74.View ArticlePubMedGoogle Scholar
  14. Ben AM, Tipton AF, Bertels Z, Gandhi R, Moye LS, Novack M, Bennett BM, Wang Y, Litosh V, Lee SH, et al. Soluble guanylyl cyclase is a critical regulator of migraine-associated pain. Cephalalgia. 2018;38(8):1471–84.View ArticleGoogle Scholar
  15. Piao ZG, Cho IH, Park CK, Hong JP, Choi SY, Lee SJ, Lee S, Park K, Kim JS, Oh SB. Activation of glia and microglial p38 MAPK in medullary dorsal horn contributes to tactile hypersensitivity following trigeminal sensory nerve injury. Pain. 2006;121:219–31.View ArticlePubMedGoogle Scholar
  16. Wu B, Wang S, Qin G, Xie J, Tan G, Zhou J, Chen L. Protein kinase C gamma contributes to central sensitization in a rat model of chronic migraine. J Mol Neurosci. 2017;63:131–41.View ArticlePubMedGoogle Scholar
  17. Pinskiy V, Tolpygo AS, Jones J, Weber K, Franciotti N, Mitra PP. A low-cost technique to cryo-protect and freeze rodent brains, precisely aligned to stereotaxic coordinates for whole-brain cryosectioning. J Neurosci Methods. 2013;218:206–13.View ArticlePubMedPubMed CentralGoogle Scholar
  18. Burnstock G. Purinergic mechanisms and pain. Adv Pharmacol. 2016;75:91–137.View ArticlePubMedGoogle Scholar
  19. Bates EA, Nikai T, Brennan KC, Fu YH, Charles AC, Basbaum AI, Ptacek LJ, Ahn AH. Sumatriptan alleviates nitroglycerin-induced mechanical and thermal allodynia in mice. Cephalalgia. 2010;30:170–8.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Olesen J. The role of nitric oxide (NO) in migraine, tension-type headache and cluster headache. Pharmacol Ther. 2008;120:157–71.View ArticlePubMedGoogle Scholar
  21. Dallel R, Descheemaeker A, Luccarini P. Recurrent administration of the nitric oxide donor, isosorbide dinitrate, induces a persistent cephalic cutaneous hypersensitivity: a model for migraine progression. Cephalalgia. 2018;38:776–85.View ArticlePubMedGoogle Scholar
  22. Harris HM, Carpenter JM, Black JR, Smitherman TA, Sufka KJ. The effects of repeated nitroglycerin administrations in rats; modeling migraine-related endpoints and chronification. J Neurosci Methods. 2017;284:63–70.View ArticlePubMedGoogle Scholar
  23. Ren K, Dubner R. Neuron-glia crosstalk gets serious: role in pain hypersensitivity. Curr Opin Anaesthesiol. 2008;21:570–9.View ArticlePubMedPubMed CentralGoogle Scholar
  24. Kraig RP, Mitchell HM, Christie-Pope B, Kunkler PE, White DM, Tang YP, Langan G. TNF-alpha and microglial hormetic involvement in neurological health & migraine. Dose Response. 2010;8:389–413.View ArticlePubMedPubMed CentralGoogle Scholar
  25. Richter F, Lutz W, Eitner A, Leuchtweis J, Lehmenkuhler A, Schaible HG. Tumor necrosis factor reduces the amplitude of rat cortical spreading depression in vivo. Ann Neurol. 2014;76:43–53.View ArticlePubMedGoogle Scholar
  26. Grinberg YY, Dibbern ME, Levasseur VA, Kraig RP. Insulin-like growth factor-1 abrogates microglial oxidative stress and TNF-alpha responses to spreading depression. J Neurochem. 2013;126:662–72.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Jander S, Schroeter M, Peters O, Witte OW, Stoll G. Cortical spreading depression induces proinflammatory cytokine gene expression in the rat brain. J Cereb Blood Flow Metab. 2001;21:218–25.View ArticlePubMedGoogle Scholar
  28. Cui Y, Takashima T, Takashima-Hirano M, Wada Y, Shukuri M, Tamura Y, Doi H, Onoe H, Kataoka Y, Watanabe Y. 11C-PK11195 PET for the in vivo evaluation of neuroinflammation in the rat brain after cortical spreading depression. J Nucl Med. 2009;50:1904–11.View ArticlePubMedGoogle Scholar
  29. Bele T, Fabbretti E. P2X receptors, sensory neurons and pain. Curr Med Chem. 2015;22:845–50.View ArticlePubMedGoogle Scholar
  30. Stokes L, Layhadi JA, Bibic L, Dhuna K, Fountain SJ. P2X4 receptor function in the nervous system and current breakthroughs in pharmacology. Front Pharmacol. 2017;8:291.View ArticlePubMedPubMed CentralGoogle Scholar
  31. Kushnir R, Cherkas PS, Hanani M. Peripheral inflammation upregulates P2X receptor expression in satellite glial cells of mouse trigeminal ganglia: a calcium imaging study. Neuropharmacology. 2011;61:739–46.View ArticlePubMedGoogle Scholar
  32. Yoon SY, Patel D, Dougherty PM. Minocycline blocks lipopolysaccharide induced hyperalgesia by suppression of microglia but not astrocytes. Neuroscience. 2012;221:214–24.View ArticlePubMedPubMed CentralGoogle Scholar
  33. Latremoliere A, Mauborgne A, Masson J, Bourgoin S, Kayser V, Hamon M, Pohl M. Differential implication of proinflammatory cytokine interleukin-6 in the development of cephalic versus extracephalic neuropathic pain in rats. J Neurosci. 2008;28:8489–501.View ArticlePubMedGoogle Scholar
  34. Hermanson O, Telkov M, Geijer T, Hallbeck M, Blomqvist A. Preprodynorphin mRNA-expressing neurones in the rat parabrachial nucleus: subnuclear localization, hypothalamic projections and colocalization with noxious-evoked fos-like immunoreactivity. Eur J Neurosci. 1998;10:358–67.View ArticlePubMedGoogle Scholar
  35. Jones MG, Lever I, Bingham S, Read S, McMahon SB, Parsons A. Nitric oxide potentiates response of trigeminal neurones to dural or facial stimulation in the rat. Cephalalgia. 2001;21:643–55.View ArticlePubMedGoogle Scholar
  36. Iyengar S, Ossipov MH, Johnson KW. The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine. Pain. 2017;158:543–59.View ArticlePubMedPubMed CentralGoogle Scholar
  37. Pardutz A, Multon S, Malgrange B, Parducz A, Vecsei L, Schoenen J. Effect of systemic nitroglycerin on CGRP and 5-HT afferents to rat caudal spinal trigeminal nucleus and its modulation by estrogen. Eur J Neurosci. 2002;15:1803–9.View ArticlePubMedGoogle Scholar
  38. Greco R, Tassorelli C, Sandrini G, Di Bella P, Buscone S, Nappi G. Role of calcitonin gene-related peptide and substance P in different models of pain. Cephalalgia. 2008;28:114–26.PubMedGoogle Scholar
  39. Bhatt DK, Gupta S, Ploug KB, Jansen-Olesen I, Olesen J. mRNA distribution of CGRP and its receptor components in the trigeminovascular system and other pain related structures in rat brain, and effect of intracerebroventricular administration of CGRP on Fos expression in the TNC. Neurosci Lett. 2014;559:99–104.View ArticlePubMedGoogle Scholar
  40. Eberhardt M, Neeb L, Vogel EM, Tiegs G, Reuter U, Messlinger K, Fischer MJ. Glyceroltrinitrate facilitates stimulated CGRP release but not gene expression of CGRP or its receptor components in rat trigeminal ganglia. Neuropeptides. 2009;43:483–9.View ArticlePubMedGoogle Scholar
  41. Matsumura Y, Yamashita T, Sasaki A, Nakata E, Kohno K, Masuda T, Tozaki-Saitoh H, Imai T, Kuraishi Y, Tsuda M, et al. A novel P2X4 receptor-selective antagonist produces anti-allodynic effect in a mouse model of herpetic pain. Sci Rep. 2016;6:32461.View ArticlePubMedPubMed CentralGoogle Scholar
  42. Buldyrev I, Tanner NM, Hsieh HY, Dodd EG, Nguyen LT, Balkowiec A. Calcitonin gene-related peptide enhances release of native brain-derived neurotrophic factor from trigeminal ganglion neurons. J Neurochem. 2006;99:1338–50.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2018

Advertisement